Results 211 to 220 of about 9,520,801 (360)
Hemophagocytic Lymphohistiocytosis as First Manifestation of Dual B-Cell Neoplasms: A Case Report of Co-Existing Multiple Myeloma and B-Cell Lymphoma. [PDF]
EJHaemRomagnoli C +6 more
europepmc +1 more source
A natural mutation of the hepatitis B virus X gene affects cell cycle progression and apoptosis in Huh7 cells [PDF]
, 2012 Chang Hee Yang +2 more
openalex +1 more source
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
The B-cell-autoantibody axis in lung cancer immunity. [PDF]
TheranosticsHuang Y, Hu H, Sun R, Wang Y.
europepmc +1 more source
T and B cell responses in different immunization scenarios for COVID-19: a narrative review [PDF]
Eva Piano Mortari +4 more
openalex +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab-Mediated B Cell Depletion in Rheumatic Diseases. [PDF]
CPT Pharmacometrics Syst PharmacolNakada T, Mager DE.
europepmc +1 more source